[ Special series on Nasopharyngeal carcinoma ]

doi: 10.1186/s40880-016-0163-6

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

Shaodong Hong and Li Zhang

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Department of Medical Oncology, Sun Yat-sen University Cancer Cente

[Abstract] For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyngeal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to determine the optimal treatment for these patients before our publication. Recently, we published an article in The Lancet entitled “Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.” The results of our study indicate that gemcitabine plus cisplatin could improve the survival of patients with recurrent or metastatic nasopharyngeal carcinoma compared with conventional fluorouracil plus cisplatin.

Chinese Journal of Cancer 2016, Volume: 35, Issue 12

[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]

[ More articles of the special series on Nasopharyngeal carcinoma ]


Cite this article

Shaodong Hong and Li Zhang. Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma. Chin J Cancer. 2016, 35:100. doi:10.1186/s40880-016-0163-6


Export citations

EndNote